Alnylam Pharmaceuticals
ALNY
#622
Rank
C$45.48 B
Marketcap
$352.65
Share price
2.75%
Change (1 day)
46.56%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2024 : C$1.87 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is C$1.87 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31C$1.73 B-3.36%
2022-12-31C$1.79 B40.91%
2021-12-31C$1.27 B91.31%
2020-12-31C$0.66 B67.47%
2019-12-31C$0.39 B871.01%
2018-12-31C$40.86 M8.35%
2017-12-31C$37.71 M-81.29%
2016-12-31C$0.20 B
2007-12-31C$6.74 M-36.62%
2006-12-31C$10.63 M23.55%
2005-12-31C$8.6 M-0.46%
2004-12-31C$8.64 M258.66%
2003-12-31C$2.41 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
C$0.73 B-60.78%๐Ÿ‡บ๐Ÿ‡ธ USA
C$3.88 B 107.71%๐Ÿ‡บ๐Ÿ‡ธ USA
C$2.00 B 7.35%๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.73 B-60.65%๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.68 M-99.96%๐Ÿ‡บ๐Ÿ‡ธ USA
C$46.20 B 2,370.29%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
C$36.58 B 1,855.76%๐Ÿ‡ซ๐Ÿ‡ท France
C$27.69 B 1,380.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel